Overview
Weight management is the most clinically validated application for peptide therapy, primarily driven by the GLP-1 receptor agonist class. The STEP and SURMOUNT trial programs produced some of the most dramatic weight loss data ever seen in pharmacological trials, fundamentally changing how physicians think about metabolic medicine.
Evidence Tiers
Tier 1: FDA-Approved, Strong RCT Evidence
Semaglutide (Wegovy / Ozempic) The STEP-1 trial demonstrated 14.9% mean body weight reduction at 68 weeks with 2.4 mg weekly semaglutide. The SELECT trial extended this, showing 20% reduction in cardiovascular events in adults with obesity (no diabetes). This is the strongest evidence base in the category.
Tirzepatide (Zepbound / Mounjaro) The SURMOUNT-1 trial showed 22.5% weight loss at 72 weeks with 15 mg tirzepatide — the largest weight loss seen in a phase 3 pharmacological trial to date. The dual GIP/GLP-1 mechanism appears to confer an advantage over pure GLP-1 agonism.
Liraglutide (Saxenda) 3 mg daily; average weight loss ~8% in trials. Less efficacious than semaglutide or tirzepatide, but a larger established evidence and safety record.
Tier 2: Research-Stage Compounds
GH Secretagogues (CJC-1295 + Ipamorelin, MK-677) Growth hormone axis modulation can improve body composition — reducing fat mass and increasing lean mass — but these compounds are not weight loss drugs. Their effect on scale weight is modest; effects on body composition are more meaningful. No RCT data in obese populations.
GHK-Cu Copper peptide with effects on metabolic gene expression. Research-grade, no human trials for weight management.
Key Considerations
- GLP-1 plateau and rebound: Weight loss with GLP-1 agonists plateaus, and weight typically rebounds substantially after discontinuation. These drugs likely require long-term use.
- Side effects: Nausea, vomiting, constipation, and gastroparesis risk are class effects of GLP-1 agonists. Rare but serious: pancreatitis, gallbladder disease, thyroid C-cell tumors (murine data — human risk unclear).
- Muscle preservation: GLP-1 weight loss includes lean mass loss. Combining with resistance training and adequate protein is standard clinical practice.
- Access: Brand-name GLP-1 agonists are expensive; compounded versions have faced increasing FDA scrutiny as the shortage designation expired.